FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma By Ogkologos - February 4, 2026 131 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BRUIN-CLL-321 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR ESMO Issues First Recommendations on Using Next-Generation Sequencing for Advanced Cancers... August 24, 2020 Osimertinib Improves Survival in Advanced Lung Cancer with EGFR Mutations December 12, 2019 Neoadjuvant Histotype-Tailored Treatment with Trabectedin Not Inferior to Standard Chemotherapy with... January 22, 2024 Reunión anual de la American Society of Clinical Oncology de 2023:... June 3, 2023 Load more HOT NEWS Picture Showing A Realistic View Of A Woman’s Milk Ducts Goes... How you can do your part in the AI transformation of... Some Children with Wilms Tumor Can Receive Less Therapy, Study Suggests ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO...
